1. |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33.
|
2. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
3. |
尹周一, 王梦圆, 游伟程, 等. 2022美国癌症统计报告解读及中美癌症流行情况对比. 肿瘤综合治疗电子杂志, 2022, 8(2): 54-63.
|
4. |
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6(5): e555-e567.
|
5. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
6. |
Zeng H, Ran X, An L, et al. Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study. Lancet Public Health, 2021, 6(12): e877-e887.
|
7. |
Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011, 6(2): 244-285.
|
8. |
Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med, 2016, 193(5): 542-551.
|
9. |
Miller DL, Mayfield WR, Luu TD, et al. Community-based multidisciplinary computed tomography screening program improves lung cancer survival. Ann Thorac Surg, 2016, 101(5): 1864-1869.
|
10. |
Horeweg N, van der Aalst CM, Thunnissen E, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med, 2013, 187(8): 848-854.
|
11. |
Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening: Results from the randomized German LUSI trial. Int J Cancer, 2020, 146(6): 1503-1513.
|
12. |
Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: Analysis of data from the randomised, controlled NELSON trial. Lancet Oncol, 2016, 17(7): 907-916.
|
13. |
Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
|
14. |
Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med, 2013, 369(10): 920-931.
|
15. |
范亚光, 周清华, 乔友林, 等. 中国肺癌低剂量CT筛查指南(2023年版). 中国肺癌杂志, 2023, 26(1): 1-9.
|
16. |
赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021, 北京). 中国肿瘤, 2021, 30(2): 81-111.
|
17. |
Vachani A, Carroll NM, Simoff MJ, et al. Stage migration and lung cancer incidence after initiation of low-dose computed tomography screening. J Thorac Oncol, 2022, 17(12): 1355-1364.
|
18. |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Lung cancer screening (version 2.2023). URL: htps:/www.nccn.org.
|
19. |
Sands J, Tammemägi MC, Couraud S, et al. Lung screening benefits and challenges: A review of the data and outline for implementation. J Thorac Oncol, 2021, 16(1): 37-53.
|
20. |
Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian early detection of lung cancer [PanCan] study): A single-arm, prospective study. Lancet Oncol, 2017, 18(11): 1523-1531.
|
21. |
Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med, 2014, 370(1): 60-68.
|
22. |
Office of the Surgeon General (US), Office on Smoking and Health (US). The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US), 2004.
|
23. |
Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: Collaborative analysis of individual data from 13 European case-control studies. BMJ, 2005, 330(7485): 223.
|
24. |
Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med, 2005, 48(6): 419-431.
|
25. |
Loomis D, Guha N, Hall AL, et al. Identifying occupational carcinogens: An update from the IARC Monographs. Occup Environ Med, 2018, 75(8): 593-603.
|
26. |
Delva F, Margery J, Laurent F, et al. Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations. BMC Public Health, 2017, 17(1): 191.
|
27. |
O'Dwyer E, Halpenny DF and Ginsberg MS. Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy? Eur Radiol, 2021, 31(1): 458-467.
|
28. |
Wu GX, Nelson RA, Kim JY, et al. Non-small cell lung cancer as a second primary among patients with previous malignancy: Who is at risk? Clin Lung Cancer, 2017, 18(5): 543-550.
|
29. |
Yang IA, Holloway JW, Fong KM. Genetic susceptibility to lung cancer and co-morbidities. J Thorac Dis, 2013, 5 (Suppl 5): S454-S462.
|
30. |
Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med, 2000, 161(1): 5-8.
|
31. |
Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium. Eur J Cancer, 2012, 48(13): 1957-1968.
|
32. |
Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med, 2013, 368(8): 728-736.
|
33. |
Tammemägi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: Screening rules applied to the PLCO and NLST cohorts. PLoS Med, 2014, 11(12): e1001764.
|
34. |
Pasquinelli MM, Tammemägi MC, Kovitz KL, et al. Risk prediction model versus united states preventive services task force lung cancer screening eligibility criteria: Reducing race disparities. J Thorac Oncol, 2020, 15(11): 1738-1747.
|
35. |
Tammemägi MC, Ten Haaf K, Toumazis I, et al. Development and validation of a multivariable lung cancer risk prediction model that includes low-dose computed tomography screening results: A secondary analysis of data from the National Lung Screening Trial. JAMA Netw Open, 2019, 2(3): e190204.
|
36. |
McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med, 2013, 369(10): 910-919.
|
37. |
Yang D, Liu Y, Bai C, et al. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett, 2020, 468: 82-87.
|
38. |
Marshall HM, Bowman RV, Yang IA, et al. Screening for lung cancer with low-dose computed tomography: A review of current status. J Thorac Dis, 2013, 5 (Suppl 5): S524-S539.
|
39. |
Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet, 2022, 399(10342): 2227-2242.
|
40. |
Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e93S-e120S.
|
41. |
Kazerooni EA, Armstrong MR, Amorosa JK, et al. ACR CT accreditation program and the lung cancer screening program designation. J Am Coll Radiol, 2016, 13(2 Suppl): R30-R34.
|
42. |
Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification: An imaging guide. J Thorac Dis, 2014, 6(Suppl 5): S537-S546.
|
43. |
Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: A statement from the Fleischner Society. Radiology, 2013, 266(1): 304-317.
|
44. |
Patz EF Jr , Greco E, Gatsonis C, et al. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: A retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol, 2016, 17(5): 590-599.
|
45. |
Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Risk stratification based on screening history: The NELSON lung cancer screening study. Thorax, 2017, 72(9): 819-824.
|
46. |
Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: Background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11(5): 681-692.
|
47. |
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med, 2020, 382(6): 503-513.
|
48. |
Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: New confirmation of lung cancer screening efficacy. Ann Oncol, 2019, 30(7): 1162-1169.
|